Novavax Inc (NVAX) - Total Liabilities
Based on the latest financial reports, Novavax Inc (NVAX) has total liabilities worth $1.19 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novavax Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how Novavax Inc's total liabilities have evolved over time, based on quarterly financial data. See Novavax Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Novavax Inc Competitors by Total Liabilities
The table below lists competitors of Novavax Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jangho Group Co Ltd
SHG:601886
|
China | CN¥20.87 Billion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
Mexico | MX$54.26 Billion |
|
Mesoblast Limited
F:LWB
|
Germany | €207.62 Million |
|
Champion Iron Ltd
TO:CIA
|
Canada | CA$1.92 Billion |
|
SK Networks Co Ltd
KO:001740
|
Korea | ₩3.22 Trillion |
|
Sylvamo Corp
NYSE:SLVM
|
USA | $1.80 Billion |
|
Solvac S.A.
BR:SOLV
|
Belgium | €215.41 Million |
|
Kernel Holding SA
WAR:KER
|
Poland | zł1.19 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Novavax Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NVAX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novavax Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novavax Inc (1996–2025)
The table below shows the annual total liabilities of Novavax Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.30 Billion | -40.29% |
| 2024-12-31 | $2.18 Billion | -13.13% |
| 2023-12-31 | $2.51 Billion | -13.08% |
| 2022-12-31 | $2.89 Billion | -1.22% |
| 2021-12-31 | $2.93 Billion | +206.55% |
| 2020-12-31 | $955.27 Million | +166.11% |
| 2019-12-31 | $358.97 Million | -4.51% |
| 2018-12-31 | $375.91 Million | -7.00% |
| 2017-12-31 | $404.23 Million | +1.09% |
| 2016-12-31 | $399.85 Million | +328.24% |
| 2015-12-31 | $93.37 Million | +101.30% |
| 2014-12-31 | $46.38 Million | +41.83% |
| 2013-12-31 | $32.70 Million | +47.94% |
| 2012-12-31 | $22.11 Million | +73.69% |
| 2011-12-31 | $12.73 Million | -19.42% |
| 2010-12-31 | $15.79 Million | +41.78% |
| 2009-12-31 | $11.14 Million | -64.22% |
| 2008-12-31 | $31.14 Million | +10.31% |
| 2007-12-31 | $28.23 Million | +1.26% |
| 2006-12-31 | $27.88 Million | -19.74% |
| 2005-12-31 | $34.73 Million | -22.33% |
| 2004-12-31 | $44.71 Million | -7.27% |
| 2003-12-31 | $48.22 Million | -2.46% |
| 2002-12-31 | $49.43 Million | +24.76% |
| 2001-12-31 | $39.62 Million | +60.38% |
| 2000-12-31 | $24.70 Million | +1353.24% |
| 1999-12-31 | $1.70 Million | +112.50% |
| 1998-12-31 | $800.00K | +166.67% |
| 1997-12-31 | $300.00K | -50.00% |
| 1996-12-31 | $600.00K | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more